



Technical Bulletin

NGS Oncology Tumor Profile Update - ComboMATCH Approved

TO: Physicians, Clinical Staff, and Clients

FROM: Dr. Christopher Lum, MD, Medical Director
Molecular Diagnostics, DLS

Dr. Amy Woron, PhD, MPH
V.P. - Technical Director
Microbiology & Molecular Labs

Dr. Wesley Kim, MD
Medical Director, DLS
and QMC West

DATE: April 7, 2025

SUBJECT: DLS NGS Oncology Tumor Profile assay approved by NCI for ComboMATCH eligibility

As of April 14, 2025 DLS joins the prestigious network of the 40 commercial and academic labs participating in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) managed by the ECOG-ACRIN Cancer Research Group. ComboMATCH evaluation will now be part of the DLS NGS Oncology Tumor Profile test. All patients will receive this evaluation allowing the oncologists or treating physicians to determine patient’s eligibility for ComboMATCH trials.

ComboMATCH is a series of precision medicine cancer clinical trials designed to evaluate the effectiveness of treating cancer with drug combinations targeting specific genetic alterations identified through the DLS NGS Oncology Tumor Profile assay, expanding the treatment options available to patients.

- Multiple treatment trials are available, enrolling patients whose tumors exhibit the targeted genetic profile
- For patients with advanced cancers – especially those who have exhausted standard therapies or have no remaining effective options – this trial offers new hope by testing promising drug combinations tailored to the unique genetic changes in their cancer
- By focusing on each patient’s individual tumor profile, ComboMATCH can identify treatments that might control the cancer when traditional treatments are no longer working, helping doctors explore better options for patients who need them most
- The drugs used in these trials are either FDA-approved for specific cancers or are currently being studied in other clinical trials, having demonstrated potential effectiveness against tumors with particular genetic changes

When a patient’s DLS NGS Oncology Tumor Profile results show alterations targeted by the drug combinations in the ComboMATCH study, the treating physician and enrollment site will work closely to review the test results and clinical data to determine eligibility and enroll the patient.

To submit your patient case for profiling, please order NGS Oncology Tumor Profile (7206)

Order Code	Test Name	Specimen Requirement	CPT
7206	NGS Oncology Tumor Profile	Formalin-Fixed Paraffin Embedded Tissue (FFPE) block	81479 or 81455

Refer any questions to Jason Pon, Manager, Molecular at (808) 441-5469 or Zan Halford, Technical Coordinator, Molecular at (808) 485-6677